Pacific Edge at risk of losing ‘significant’ revenue stream

Pacific Edge at risk of losing ‘significant’ revenue stream
The test has been used more than 10,000 times since it was first approved in 2020. (Image: Pacific Edge)
Dan Brunskill
Pacific Edge could have its cancer tests dropped by a major US health insurance company which is considering a new way to choose which tests are covered.  Medicare provider Novitas currently reimburses the use of Cxbladder but would not under a new process it has proposed. Currently, the health insurer reviews clinical evidence for each individual product but has proposed relying on third-party lists instead. Pacific Edge said if the proposal was adopted, Cxbladder would no longer receive reimbursement from Novitas, which makes up &ld...

More Markets

NZ market rises on potential for more Chinese stimulus
Markets Market Close

NZ market rises on potential for more Chinese stimulus

Overnight US bond yields were down.

Graham Skellern 04 Oct 2024
Blackpearl seeks $10m to help win higher-value customers
Markets

Blackpearl seeks $10m to help win higher-value customers

The NZX-listed company’s customers are primarily US-based.

Ben Moore 04 Oct 2024